Heron Therapeutics (HRTX) Expected to Release Earnings on Tuesday

Heron Therapeutics (NASDAQ:HRTX) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $37.50 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter. The firm had revenue of $37.67 million for the quarter, compared to analysts’ expectations of $42.19 million. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. On average, analysts expect Heron Therapeutics to post ($0.14) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $0.30 on Tuesday. The firm’s 50 day simple moving average is $0.33 and its 200-day simple moving average is $0.72. The company has a market cap of $57.09 million, a P/E ratio of -1.58 and a beta of 1.62. The company has a debt-to-equity ratio of 24.35, a current ratio of 2.49 and a quick ratio of 1.51. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57.

Analyst Ratings Changes

Several equities research analysts recently commented on HRTX shares. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th. Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Heron Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $2.00.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.